E-Cigarettes or Medication for Tobacco Use
(STEPS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether switching to e-cigarettes or using nicotine patches and lozenges can help people quit smoking, particularly those undergoing treatment for substance use disorder. Participants will use either e-cigarettes or a combination of nicotine patches and lozenges for 12 weeks. The trial is open to individuals who smoke at least five cigarettes daily and have recently begun outpatient treatment for substance use disorder. Participants should have attempted to quit smoking before and be interested in reducing or quitting smoking. The study will occur in three locations across South Carolina. As an unphased trial, this study offers a unique opportunity to contribute to research that could enhance smoking cessation strategies for individuals with substance use disorders.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot be using any current medication for smoking cessation.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that e-cigarettes are generally perceived as safer than regular cigarettes and are about as safe as other approved methods for quitting smoking, such as nicotine patches or lozenges. However, e-cigarettes carry risks. They often contain nicotine, which is addictive and can harm health. The long-term effects of using e-cigarettes remain unclear.
Nicotine replacement therapy (NRT), including patches and lozenges, is well-researched and widely used to aid smoking cessation. Studies have found that NRT can nearly double the chances of quitting. While NRT can cause some side effects, they are usually not serious or life-threatening.
Both e-cigarettes and NRT in this trial are considered relatively safe, but each has its own risks. Choosing between them might depend on individual preference and specific health needs.12345Why are researchers excited about this trial's treatments?
Researchers are excited about these treatments for quitting tobacco use because they offer new approaches that might be more effective for some people. Unlike traditional methods like nicotine patches or gum, switching to e-cigarettes provides a familiar smoking experience without the harmful tobacco smoke. This might help ease the transition for smokers. On the other hand, the medication approach uses a combination of nicotine patches and lozenges to provide a steady release of nicotine, potentially reducing withdrawal symptoms. Both methods aim to support smokers in quitting by addressing different aspects of their addiction.
What evidence suggests that this trial's treatments could be effective for quitting smoking?
Research on using e-cigarettes to quit smoking has shown mixed results. Some studies suggest that e-cigarettes can aid quitting more effectively than counseling alone, while others find they don't consistently improve quitting rates. In this trial, participants in one arm will switch to an e-cigarette for 12 weeks. Conversely, nicotine replacement products like patches and lozenges are known to help with withdrawal and cravings. Participants in another arm of this trial will receive combination nicotine replacement therapy (NRT) with transdermal patches and nicotine lozenges for 12 weeks. A review of several studies found that using nicotine therapy with some support can lead to about a 15.2% quit rate over six months. Both methods can be effective, but success depends on the individual and the support received.678910
Are You a Good Fit for This Trial?
The STEPS trial is for individuals who smoke and are currently in treatment for substance use disorder. Participants must have joined a SUD program within the last 30 days and be willing to try quitting smoking by either switching to e-cigarettes or using FDA-approved nicotine replacement therapies, along with counseling.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to either switch to e-cigarettes or use nicotine replacement therapy for 12 weeks
Follow-up
Participants are monitored for smoking abstinence and treatment outcomes after the end of the treatment phase
What Are the Treatments Tested in This Trial?
Interventions
- Counseling
- Quitting using Medication
- Switching to E-Cigarette
Trial Overview
This study compares the effectiveness of e-cigarettes versus nicotine patches and lozenges in helping people quit smoking during their substance use disorder treatment. It includes five in-person visits and eleven virtual check-ins over six months, plus daily diary entries via phone for twelve weeks.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
This arm includes participants randomly assigned to the E-Cigarette Group. Participants will receive a study-provided e-cigarette product for 12 weeks.
This arm includes participants randomly assigned to the medication group. Participants will receive combination nicotine replacement therapy (NRT). The NRT will consist of transdermal patches and nicotine lozenges. Participants will receive study product for 12 weeks.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medical University of South Carolina
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Published Research Related to This Trial
Citations
Nicotine Replacement Therapy - StatPearls - NCBI Bookshelf
NRTs are designed to replicate the nicotine response typically experienced through smoking, thereby helping individuals manage cravings and withdrawal symptoms.
2.
tobaccopreventioncessation.com
tobaccopreventioncessation.com/The-effectiveness-of-nicotine-replacement-therapy-on-oral-smokeless-tobacco-cessation,208023,0,2.htmlThe effectiveness of nicotine replacement therapy on oral ...
A previous systematic review found that nicotine patches or gum did not receive much evidence to help individuals abstain from using smokeless ...
Effectiveness of Nicotine Replacement Therapy and ...
In a meta-analysis, the combination of pharmacotherapy and BI was associated with a quit rate of 15.2% over 6 months; in contrast, brief advice or usual care ...
Nicotine Patch vs. Nicotine Lozenge for Smoking Cessation
Conclusions: Transdermal nicotine may be more effective than nicotine lozenge for smokers who prefer transdermal nicotine and do not smoke to alleviate ...
5.
truthinitiative.org
truthinitiative.org/research-resources/quitting-smoking-vaping/quitting-tobacco-facts-and-statsQuitting Tobacco: Facts and Stats
In 2020, 8.5% of adult current smokers successfully quit smoking in the past year, up from 7.5% in 2018.
Health Effects of Vaping | Smoking and Tobacco Use
No tobacco products, including e-cigarettes, are safe. Most e-cigarettes contain nicotine, which is highly addictive and is a health danger for ...
Tobacco: E-cigarettes
Evidence reveals that these products are harmful to health and are not safe. However, it is too early to provide a clear answer on the long-term impact of using ...
Health Risks of E-Cigarettes and Vaping
The Food and Drug Administration has not found any e-cigarette to be safe and effective in helping people who use tobacco products to quit. If ...
Safety and Efficacy of Electronic Cigarettes: A Review - PMC
Electronic cigarettes are safer than conventional cigarettes and at least as safe as other approved nicotine replacement therapies.
10.
hopkinsmedicine.org
hopkinsmedicine.org/health/wellness-and-prevention/5-truths-you-need-to-know-about-vaping5 Vaping Facts You Need to Know
Smoking electronic cigarettes is often considered safer than regular smoking. Learn facts about vaping and why you should rethink taking it up.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.